Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

BACKGROUND: Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new antidiabetic drug classes remains unclear. We therefore performed a network met...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Yue, Tsoi, Man-Fung, Cheung, Bernard Man Yung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714383/
https://www.ncbi.nlm.nih.gov/pubmed/31462224
http://dx.doi.org/10.1186/s12933-019-0916-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714383/
https://www.ncbi.nlm.nih.gov/pubmed/31462224
http://dx.doi.org/10.1186/s12933-019-0916-z

Ejemplares similares